Damora Therapeutics (DMRA) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed MannKind (MNKD) over the past year, gaining 12.9% versus a loss of 37.1%. Over five years, MNKD leads with a -32.8% price change compared with -76.3% for DMRA. Damora Therapeutics is the larger company by market cap ($1.27 billion vs $1.10 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | MNKD |
|---|---|---|
| Share price | $20.56 | $3.42 |
| Market cap | $1.27B | $1.10B |
| 1-day change | +1.58% | -0.87% |
| YTD return | -12.04% | -39.68% |
| 1-year return | +12.95% | -37.13% |
| 5-year return | -76.33% | -32.81% |
| Forward P/E | — | 26.82 |
| EPS (TTM) | $-0.25 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $6.51 |
| 52-week low | $4.95 | $2.23 |
| Distance from 52-week high | -46.35% | -47.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.06% | +129.24% |
| Average volume | 531.94K | 4.50M |
| Shares outstanding | 61.74M | 321.54M |
| Employees | 7 | 591 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed MNKD by 50.1 percentage points over the past year.
- The two companies sit in different sectors: Damora Therapeutics in Health Care and MannKind in Healthcare.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Healthcare · Biotechnology · 591 employees
DMRA vs MNKD FAQ
Which is bigger, Damora Therapeutics or MannKind?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.27B compared with $1.10B for MannKind (MNKD).
Which stock has performed better over the past year, DMRA or MNKD?
DMRA returned +12.95% over the past 12 months, compared with -37.13% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and MannKind in the same industry?
No. Damora Therapeutics is in the Health Care sector, while MannKind is in Healthcare.